Balversa erdafitinib

  • Brand Name: Balversa
  • Innovator Brand Name: Balversa
  • API: Erdafitinib
  • Dosage Form: 28/56/84 Tablets
  • Strength: 3/4/5mg
  • Manufacturer Name: Janssen Pharma
Get Price

Description

Balversa Uses

Balversa (Erdafitinib) is a kinase inhibitor used to treat adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3/FGFR2 genetic alterations and progressed during or after at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Dosage: The recommended starting dose of Erdafitinib is 8 mg (two 4 mg tablets) orally once a day, with a dose increase to 9 mg (three 3 mg tablets) once a day based on the serum phosphate (PO4) levels and tolerability at 14-21 days. Swallow tablets of Erdafitinib whole either with or without food. If vomiting occurs any time after taking the erdafitinib dose, the next dose should be administered the next day. Treatment should continue until disease progression or unacceptable toxicity occurs. If a dose of erdafitinib is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for Erdafitinib the next day. Extra pills should not be taken in order to make up for the missed dose.

Side Effects: The most commonly reported balversa side effects include:

  • Increased phosphate level
  • Mouth sores
  • Feeling tired
  • Change in kidney function
  • Diarrhea
  • Dry mouth
  • Dry skin
  • Dry eyes
  • Hair loss
  • Change in liver function
  • Low salt (sodium) levels
  • Decreased appetite
  • Change in sense of taste
  • Low red blood cells (anemia)

Warnings and Precautions:

  • Monthly ophthalmological assessment should be performed during the first 4 months of therapy and every 3 months afterwards, and urgently at any time for visual symptoms.
  • Monitor patients with balversa dose for hyperphosphatemia and follow the dose modification guidelines when required.
  • Erdafitinib can cause fetal harm if used by a pregnant woman. Advise females of reproductive potential to consider apt contraception during therapy with Erdafitinib and for 1-month after the last dose.
  • Due to the risk for serious adverse events from erdafitinib tablets in a breastfed child, lactating women are advised to avoid breastfeeding during treatment with and for one month following the last dose.
  • As per the findings/data from animal studies, the balversa uses may impair fertility in females of reproductive potential.

More info

Storage: Store Erdafitinib Tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the BALVERSA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the BALVERSA Tablets. Buying Procedure: In order to buy BALVERSA, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusion: Erdafitinib is a once-daily oral therapy and the first FGFR kinase inhibitor approved by FDA. It may improve outcomes for recipients with urothelial carcinoma and FGFR genetic alterations. This FDA-approval provides a new treatment option and the first targeted therapy for recipients with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/FGFR2 genetic alterations, or for those whose disease progressed during or following ≥1 lines of platinum-containing chemotherapy.

FAQ

What is Balversa? Balversa specifically is a small molecule inhibitor of FGFR (fibroblast growth factor receptor) approved to treat cancer. What does Balversa contain as an active substance? The medication Balversa specifically contains the active substance Erdafitinib. How is Erdafitinib supplied? Erdafitinib is supplied as tablets, 3/4/5mg for oral administration. Is Erdafitinib chemotherapy? Erdafitinib is the first targeted therapy that the USFDA approved for treatment of patients with metastatic bladder cancer. How much does balversa cost? The balversa price in India usually can vary depending on the wholesaler/pharmacy you visit. Balversa is available as a brand name drug only, a generic version is not yet available. What is the best price for Erdafitinib? Please contact Toll-free: +91 1800 889 1064|+919310090915 for erdafitinib price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Balversa (Erdafitinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Balversa (Erdafitinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

×